The present clinical trial investigated the safety and maximum tolerated dose (MTD) of the combination therapy of metformin and chloroquine in patients with IDH1-mutated chondrosarcoma, glioma and intrahepatic cholangiocarcinoma. The gene discussed is IDH1; the disease is glioma.